Guanhao Biotech Co Ltd (300238) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guanhao Biotech Co Ltd (300238) has a cash flow conversion efficiency ratio of 0.037x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥18.84 Million ≈ $2.76 Million USD) by net assets (CN¥506.03 Million ≈ $74.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guanhao Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Guanhao Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Guanhao Biotech Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Guanhao Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guanhao Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
American Coastal Insurance Corp
NASDAQ:ACIC
|
-0.150x |
|
COINSHARES I. LS-000247
F:3TW
|
N/A |
|
Palm Landscape Architecture Co Ltd
SHE:002431
|
0.097x |
|
Delpha Construction Co Ltd
TW:2530
|
0.071x |
|
Shenzhen Ruihe Construction Decoration Co Ltd
SHE:002620
|
0.206x |
|
Compania General de Electricidad SA
SN:CGE
|
-0.004x |
|
Shinsung E&G Co. Ltd
KO:011930
|
0.023x |
|
Ningbo Gaofa Automotive Ctrl
SHG:603788
|
0.071x |
Annual Cash Flow Conversion Efficiency for Guanhao Biotech Co Ltd (2007–2025)
The table below shows the annual cash flow conversion efficiency of Guanhao Biotech Co Ltd from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see 300238 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥506.03 Million ≈ $74.05 Million |
CN¥71.47 Million ≈ $10.46 Million |
0.141x | +33.28% |
| 2024-12-31 | CN¥467.59 Million ≈ $68.42 Million |
CN¥49.55 Million ≈ $7.25 Million |
0.106x | -10.70% |
| 2023-12-31 | CN¥456.26 Million ≈ $66.77 Million |
CN¥54.15 Million ≈ $7.92 Million |
0.119x | -27.96% |
| 2022-12-31 | CN¥430.88 Million ≈ $63.05 Million |
CN¥70.98 Million ≈ $10.39 Million |
0.165x | +0.70% |
| 2021-12-31 | CN¥748.16 Million ≈ $109.48 Million |
CN¥122.39 Million ≈ $17.91 Million |
0.164x | +12.91% |
| 2020-12-31 | CN¥716.66 Million ≈ $104.87 Million |
CN¥103.84 Million ≈ $15.19 Million |
0.145x | +10.24% |
| 2019-12-31 | CN¥704.14 Million ≈ $103.04 Million |
CN¥92.55 Million ≈ $13.54 Million |
0.131x | +370.53% |
| 2018-12-31 | CN¥1.16 Billion ≈ $169.08 Million |
CN¥32.28 Million ≈ $4.72 Million |
0.028x | +76.29% |
| 2017-12-31 | CN¥1.21 Billion ≈ $177.49 Million |
CN¥19.22 Million ≈ $2.81 Million |
0.016x | -24.74% |
| 2016-12-31 | CN¥1.46 Billion ≈ $213.26 Million |
CN¥30.68 Million ≈ $4.49 Million |
0.021x | -80.75% |
| 2015-12-31 | CN¥620.62 Million ≈ $90.82 Million |
CN¥67.87 Million ≈ $9.93 Million |
0.109x | -11.18% |
| 2014-12-31 | CN¥531.61 Million ≈ $77.79 Million |
CN¥65.45 Million ≈ $9.58 Million |
0.123x | +47.83% |
| 2013-12-31 | CN¥498.16 Million ≈ $72.90 Million |
CN¥41.49 Million ≈ $6.07 Million |
0.083x | -23.01% |
| 2012-12-31 | CN¥454.11 Million ≈ $66.45 Million |
CN¥49.12 Million ≈ $7.19 Million |
0.108x | +32.06% |
| 2011-12-31 | CN¥432.79 Million ≈ $63.33 Million |
CN¥35.45 Million ≈ $5.19 Million |
0.082x | -64.81% |
| 2010-12-31 | CN¥144.99 Million ≈ $21.22 Million |
CN¥33.76 Million ≈ $4.94 Million |
0.233x | +222.72% |
| 2009-12-31 | CN¥76.95 Million ≈ $11.26 Million |
CN¥5.55 Million ≈ $812.33K |
0.072x | -44.41% |
| 2008-12-31 | CN¥37.01 Million ≈ $5.42 Million |
CN¥4.80 Million ≈ $702.80K |
0.130x | +55.21% |
| 2007-12-31 | CN¥20.67 Million ≈ $3.02 Million |
CN¥1.73 Million ≈ $252.86K |
0.084x | -- |
About Guanhao Biotech Co Ltd
Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products primarily in China. It offers NormalGEN, a dura repair patch; GrandNeuro, a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological … Read more